ARTICLE | Emerging Company Profile
Hangzhou Highlightll: Twice the target, hold the tox
TYK2/JAK1 inhibitor could treat a broad range of autoimmune diseases
July 3, 2021 2:04 AM UTC
Sutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer ...